Beta2-ADRENOCEPTOR AGONIST FOR THE TREATMENT OF COUGH

• US 20160074410A1
• Filed: 11/24/2015
• Published: 03/17/2016
• Est. Priority Date: 10/09/2012
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Bouyssou, Thierry, Pieper, Michael Paul
• Application Number:
  US14/950,037
• Publication Number:
  US 20160074410A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/439 the ring forming part of a bridged ring system, e.g. quinuclidine 8-azabicyclo [3.2.1] octanes A61K31/46
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/538 ortho- or peri-condensed with carbocyclic ring systems
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61P 11/14 Antitussive agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

This invention relates to the β2-adrenoceptor agonist Olodaterol or a pharmaceutically acceptable salt thereof,

for use in a method of treatment of cough from various origins.

Claims

1. A method of treating cough in a patient comprising administering to said patient Olodaterol or a pharmaceutically acceptable salt thereof,

wherein 5 μ

g of olodaterol or an amount of a pharmaceutically acceptable salt of olodaterol equivalent to 5 μ

g of olodaterol is administered to the patient,

wherein olodaterol is administered to the patient through two actuations of 2.7 μ

g olodaterol hydrochloride each.

5. The method according to claim 1, wherein the method comprises administering to said patient Olodaterol hydrochloride in a once daily, inhalative dosage.

6. The method according to claim 1, wherein the method comprises co-administration of a tiotropium salt.

7. The method according to claim 6, wherein the tiotropium salt is tiotropium bromide.

8. The method according to to claim 7, wherein the tiotropium bromide is administered in a dosage from 1 to 50 μ

g.

9. The method according to to claim 8, wherein the tiotropium bromide is administered in a once daily, inhalative dosage.

10. The method according to claim 1, wherein said administration of olodaterol or a pharmaceutically acceptable salt thereof does not cause addiction or arrhythmia in said patient.

11. The method according to claim 1, wherein the heart rate of the patient is not increased.

2. (canceled)

3. (canceled)

4. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)